ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. - Wikidata - wikimedia - TriplyDB

ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.

ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.

http://www.wikidata.org/entity/Q44594549

about

EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance The anti-apoptotic effect of regucalcin is mediated through multisignaling pathways Pterostilbene-isothiocyanate conjugate suppresses growth of prostate cancer cells irrespective of androgen receptor status Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells Co-activation of ERK, NF-kappaB, and GADD45beta in response to ionizing radiation.Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers.Development of a growth-hormone-conjugated nanodiamond complex for cancer therapy.Apoptotic Effect of Geniposide on Fibroblast-Like Synoviocytes in Rats with Adjuvant-Induced Arthritis via Inhibiting ERK Signal Pathway In Vitro.Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer Overcoming drug resistance and treating advanced prostate cancer Garlic arrests MDA-MB-435 cancer cells in mitosis, phosphorylates the proapoptotic BH3-only protein BimEL and induces apoptosis.Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals Schlafen 3 induction by cyclic strain regulates intestinal epithelial differentiation.Nerve growth factor promotes endothelial progenitor cell-mediated angiogenic responses TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion From bench to bedside: the growing use of translational research in cancer medicine.CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.Reconstitution of anti-allergic activities of PG102 derived from Actinidia arguta by combining synthetic chemical compounds.ICB3E induces iNOS expression by ROS-dependent JNK and ERK activation for apoptosis of leukemic cells.Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.Essential oil of Curcuma wenyujin induces apoptosis in human hepatoma cells.Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.Phosphorylation of BAD at Ser-128 during mitosis and paclitaxel-induced apoptosis.Tricetin Induces Apoptosis of Human Leukemic HL-60 Cells through a Reactive Oxygen Species-Mediated c-Jun N-Terminal Kinase Activation Pathway.Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer.Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.Low concentration of formononetin promotes proliferation of estrogen receptor-positive cells through an ERα-miR-375-PTEN-ERK1/2-bcl-2 pathway.Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059.Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression.PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment.Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.MAPK/c-Jun signaling pathway contributes to the upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL induced by Epstein-Barr virus-encoded BARF1 in gastric carcinoma cells.Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis.

P2860

Q24646417-0DCB3329-8716-4FCE-BD25-3D6BC842731A Q27004426-B356FB73-ED4C-4F5D-87B6-FE248F2E64CC Q28541923-75869A3A-D2A7-4149-B2DC-00FE6D6DDEDB Q33596742-E2DBBA52-4402-49CB-BE20-01EABB0F3340 Q34033277-35F2F335-E578-4234-848F-EECCA9DF964D Q34115708-AC9B9938-F9A3-4A1C-A191-8EA67B3A1577 Q34646291-DDFA54F9-1610-4FFB-8B93-19B57758AD2F Q35134093-833B47BD-9A69-4478-9BEA-F8264D71732C Q35732956-94CEC7F9-183D-48B6-AC79-E312AC5782EB Q35749794-39A6DE41-091E-4844-930D-C21E203C7A3E Q36241242-5011B26A-C9C3-4944-98DD-5AEDDC06C051 Q36328812-DB195DC5-F357-42B4-84CD-1968DD1CA8DF Q36616887-F3770872-FE5E-4206-8375-187F0F4121DD Q36738823-A277D6E2-BF13-435A-8E48-24CF6F97D34C Q36895862-F43BBD16-50C8-4AAC-8FDF-37CC5446D637 Q37013867-67872D47-BC90-49CC-833E-50EC9B8DF6FB Q37481085-363F6BCD-E392-4452-A1B4-37FB433837A9 Q37643454-2E6D75CB-EE83-4C7A-8C9D-ED1EBAB594FB Q37698244-A6F66C64-555E-49A5-A71E-A57E4CBDD208 Q38943604-E06D4AC1-B3BC-4D20-8C56-AA1BEB3D55E2 Q39114807-732B1DA5-3661-4548-961E-533E10CB8C80 Q39410900-0077BA82-2427-4028-A28A-73816B2C51B4 Q39847370-0E9077EA-97C4-47DC-AE83-0AD81045011C Q39955965-736630ED-FCF8-46D1-8757-B7002A0E90F5 Q40262420-2EB86556-F63A-45E7-9129-C72C4623F698 Q40419498-C6E4D982-CD0A-4E66-81C7-AAF1A9E40D2C Q41573365-C0CAE2BC-7384-4162-A4A8-9776FD9F76A7 Q41883096-4F90BA08-05A1-4CC2-83B2-D5B42771FC76 Q41947893-6EF6D706-E078-4F8F-8B2A-5AEFE9284744 Q43199031-45E39C4B-DA9B-4E63-8D14-2F82CF4B05FA Q47127001-033DB140-0D37-4EAA-BCB4-97C7709D93B3 Q47772398-7878F2B1-C7C7-4D1D-916D-DDC76B847D1D Q47941645-5324A147-B5AF-4568-AEF0-5C0A4C31B895 Q50157919-89FBC5A8-6676-4DAD-9842-631D7BD3F87C Q50523554-1C078C02-D541-43C6-BD28-44D68421EE7E Q51604439-1E634112-69B5-4EA9-8A4C-73D3282B5874 Q54112433-4D5CEFDD-DCD5-4D3B-8EB1-1A8DEBC7FA9D Q54977122-7581A372-B0A9-489F-A262-C8C382690CC8

P2860

ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.

http://www.wikidata.org/entity/Q44594549

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

ERK inhibitor PD98059 enhances ...... t human prostate cancer cells.

@en

ERK inhibitor PD98059 enhances ...... t human prostate cancer cells.

@nl

type

label

ERK inhibitor PD98059 enhances ...... t human prostate cancer cells.

@en

ERK inhibitor PD98059 enhances ...... t human prostate cancer cells.

@nl

prefLabel

ERK inhibitor PD98059 enhances ...... t human prostate cancer cells.

@en

ERK inhibitor PD98059 enhances ...... t human prostate cancer cells.

@nl

P1433

Q44594549-8E9B798C-7E0F-4495-ACD6-AA534E963351

P1476

Q44594549-F128DA5D-3D86-425C-8D22-2BDD4D31B352

P2093

Q44594549-2A5B58E0-0A1B-4F34-99B6-AE4043CF17BC

Q44594549-4261EACB-BDE3-43BC-9731-DBA1F7572FEE

Q44594549-4AFCBAA6-D4A1-4683-94F5-28B93D6F179E

Q44594549-537E4726-3E98-460D-9215-124876B4322E

Q44594549-7476094E-F2BE-4115-8F6A-BC3C99354197

Q44594549-7C4892ED-9C04-4C14-8D4E-C2BE659AE1BB

Q44594549-A3DC8A23-0EB2-4853-A25C-56C81AAFC5C0

Q44594549-C01F0BD4-7537-4503-9986-AA62F786818D

Q44594549-C18F3F1E-75B1-4725-BEEB-5F9A7354E661

Q44594549-FC603CDE-1975-4835-9A60-B67C303520B4

P304

Q44594549-C5A0728D-A6E6-45E5-A72E-255980049F69

P31

Q44594549-D1193C08-6469-4570-A07C-015F721CD388

P356

Q44594549-79B4E3E1-7896-41DD-8C2A-AF3135F8AE10

P433

Q44594549-AB7AD42C-3CF0-43CF-B6A1-98D6D5CC800F

P478

Q44594549-399F76F0-8545-497C-B4C2-9063CDCB734C

P50

Q44594549-7C537FED-FFDF-49AE-B241-B08F64B41F9E

Q44594549-FE11A14F-D7F1-4F25-9756-29A2FDA02AD6

P577

Q44594549-BBAA6E4E-9FAF-4FD8-BF22-1AA7A61DD614

P5875

Q44594549-22AED281-CD8F-446D-B53B-9DDAD182CFEE

P698

Q44594549-B1471BC3-D094-4113-A1E5-2F99DF76A237

P356

P1433

International Journal of Cancer

P1476

ERK inhibitor PD98059 enhances ...... nt human prostate cancer cells

@en

P2093

Esmeralda Lugo

http://www.w3.org/2001/XMLSchema#string

Mark Kellerman

http://www.w3.org/2001/XMLSchema#string

Matthew Spellman

http://www.w3.org/2001/XMLSchema#string

Ming-Fong Lin

http://www.w3.org/2001/XMLSchema#string

Ralph Hauke

http://www.w3.org/2001/XMLSchema#string

Rodney Taylor

http://www.w3.org/2001/XMLSchema#string

Stanislav Zelivianski

http://www.w3.org/2001/XMLSchema#string

Thomas L Davis

http://www.w3.org/2001/XMLSchema#string

Vladimir Kakitelashvilli

http://www.w3.org/2001/XMLSchema#string

Xia-Wei Zhou

http://www.w3.org/2001/XMLSchema#string

P304

478-485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.11413

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9082482

http://www.w3.org/2001/XMLSchema#string

P698

14506750

http://www.w3.org/2001/XMLSchema#string